• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
OB

Fetal Growth Restriction: Definition, Evaluation and Management

image_pdfFavoriteLoadingFavorite

SUMMARY:

ACOG / SMFM released a guidance update on fetal growth restriction (FGR). While there is currently no clear consensus on the definition, evaluation, and management, FGR is associated with adverse perinatal outcomes. Therefore, timely diagnosis and management are key to optimizing long term benefit. Ultrasound and fundal height measurement are important physical exam diagnostic maneuvers. Early delivery and expectant management have similar outcomes thus creating deliberate birth plans should be discussed.

Key Terms and Definitions

  • FGR: EFW or AC <10th percentile for gestational age
    • Symmetric: Global growth restriction | Early insult
    • Asymmetric: Head-sparing with generally better outcomes
  • Small for gestational age (SGA): Newborn birthweight <10th percentile for gestational age

Risk Factors

Maternal Disease

  • Hypertensive disorders
    • Chronic hypertension
    • Gestational hypertension and preeclampsia
  • Kidney disease
  • Endocrine
    • Pregestational diabetes mellitus
  • Autoimmune
    • SLE
    • Antiphospholipid syndrome
  • Congenital heart disease (see ‘Learn More – Primary Sources’ for additional information)
    • Highest risk: Cyanotic heart disease | Reduced cardiac output

Note: Nutrition, oxygenation, and cardiovascular adaptation to pregnancy (placental perfusion) are underlying maternal factor mechanisms that impact fetal growth

Fetal Factors

  • Multiple gestation
  • Teratogenic exposures
    • Medications (e.g. fetal hydantoin syndrome)
    • Substance abuse (modifiable risk) including alcohol, cocaine and smoking
    • Intrauterine infections (e.g., CMV, rubella, syphilis)
  • Genetics:
    • Aneuploidy: Trisomy 13 and trisomy 18 commonly associated with FGR
    • Single gene disorders
    • Multifactorial: Congenital malformations (heart disease, gastroschisis)

Placental Anomalies

  • Abruption | Infarction | Circumvallate shape | Hemangioma | Chorioangioma
  • Umbilical cord anomalies
    • Velamentous or marginal insertion
    • Single umbilical artery

Note: Placental implantation abnormalities (e.g. placental accreta spectrum, previa) not associated with FGR

Evaluation and Screening Methods

  • Fundal height measurements
    • Begin at 24 weeks gestation
    • Perform at each prenatal visit
    • 3 cm discrepancy “proposed for identifying a fetus that may be growth restricted”
    • Limitations
      • Maternal obesity | Fibroids | Multiple gestation
  • Ultrasound
    • Preferred method of evaluation
    • Measurements include
      • BPD
      • HC
      • AC
      • FL
  • UA Doppler velocimetry
    • Reduces perinatal death when added to antepartum testing
    • Absent or reversed end-diastolic flow increases risk for perinatal mortality
    • Evaluation of the fetal ductus venosus has not been shown to improve perinatal outcomes (TRUFFLE study)

Note: No current evidenced based screening methods or preventative measures such as bed rest have demonstrated improved perinatal outcomes

KEY POINTS:

Management

  • Address modifiable risk factors, for example
    • Screen for fetal alcohol exposure
    • Discuss and encourage reduction in smoking and/or smoking cessation
      • Smoking is associated with 3.5 increased risk of SGA newborns
  • Genetic counseling
    • FGR alone may be associated with genetic syndromes and aneuploidy
    • Combined FGR and fetal structural abnormalizes increase aneuploidy risk and warrants genetic counseling referral
  • Depending on clinical scenario
    • Serial ultrasounds q3-4 weeks for growth and AFV
    • Do not measure fetal growth more often than every 2 weeks (measurements will be within error of the test)
    • Fetal assessment (NSTs or BPPs): “…should not begin before a gestational age when delivery would be considered for perinatal benefit”
  • Mode of delivery
    • Reserve cesarean section for obstetric/neonatal indications
    • Cesarean section and is not indicated for FGR in isolation

Timing of Delivery

  • Normal UA Doppler and EFW 3 to 10th percentile: 38w0d to 39w0d
  • EFW <3rd percentile (severe FGR): 37w0d
  • Decreased UA flow without absent end diastolic flow: 37w0d to 37w6d
  • Absent end diastolic flow: 33w0d to 34w0d
  • Reversed end diastolic flow: 30w0d to 32w0d
  • With oligohydramnios or concurrent conditions (e.g., preeclampsia, chronic hypertension): 34w0d to 37w6d

Note: If delivery planned <34 weeks, deliver at center with a NICU and consult MFM

When to Give Antepartum Corticosteroids

  • < 33w6d (anticipated delivery)
  • 34w0d-36w6d (late preterm) if risk
    • No previous corticosteroids
    • Anticipate delivery within 7 days

Note: “Consider” magnesium sulfate (neuroprotection) if delivery <32w0d

Future Pregnancies

  • Counsel regarding 20% recurrence risk
  • Review history to identify modifiable factors and/or treat maternal disease
  • In subsequent pregnancies

…it may be reasonable to perform serial ultrasonography for growth assessment, although the optimal surveillance regimen has not been determined.

Maternal history of a prior SGA newborn with normal fetal growth in the current pregnancy is not an indication for antenatal fetal heart rate testing, biophysical profile testing, or umbilical artery Doppler velocimetry

Note: There is insufficient evidence to routinely administer aspirin to prevent SGA in this population

Learn More – Primary Sources

ACOG Practice Bulletin 227: Fetal Growth Restriction

Effect of Maternal Heart Disease on Fetal Growth

Locate a Maternal Fetal Medicine Specialist

Maternal Fetal Medicine Specialist Locator-SMFM

Get Guideline Notifications Direct to Your Phone

ObGFirst® – Try It Free! >>

image_pdfFavoriteLoadingFavorite
< Previous
All OB Posts
Next >

Related ObG Topics:

Antenatal Corticosteroids – When to Administer?
ACOG Recommendations: When to Deliver Medically Complicated Pregnancies
Fetal Alcohol Spectrum Disorders – CDC Summary and Updates
SMFM Recommendations: FGR Diagnosis and Management

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site